DMD and Duchenne muscular dystrophy: Golodirsen, developed by Sarepta Therapeutics and granted FDA approval on 12 December 2019, is indicated for treating Duchenne muscular dystrophy (DMD) in patients with dystrophin gene mutations by promoting the skipping of exon 53 [126].